info@seagull-health.com
SeagullHealth
search
Capivasertib(Truqap)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Truqap(Capivasertib) Instructions:Uses,Dosage, Side Effects
TRUQAP (capivasertib) is an orally administered kinase inhibitor developed by AstraZeneca. It received its initial U.S. approval in 2023. The drug specifically targets and inhibits all three isoforms (AKT1, AKT2, AKT3) of the serine/threonine kinase AKT. It is formulated as film-coated tablets available in two strengths and is used in combination with fulvestrant for a specific subset of advanced breast cancer.
Indicated in combination with fulvestrant for adult patients with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer harboring one or more alterations in PIK3CA, AKT1, or PTEN, as detected by an FDA-approved test, following disease progression on or after endocrine therapy.
The recommended dose is 400 mg taken orally twice daily (approximately 12 hours apart) with or without food, administered for 4 consecutive days followed by 3 days off each week. Treatment should continue until disease progression or unacceptable toxicity. Dose modifications are recommended for adverse reactions and concomitant use with CYP3A inhibitors.
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- mailbox：info@lucius.la
